Maarten C C M Hulshof1, Elisabeth D Geijsen1, Tom Rozema2, Vera Oppedijk3, Jeroen Buijsen4, Karen J Neelis5, Joost J M E Nuyttens6, Maurice J C van der Sangen7, Paul M Jeene8, Jannie G Reinders9, Mark I van Berge Henegouwen10, Adriana Thano11, Jeanin E van Hooft12, Hanneke W M van Laarhoven13, Ate van der Gaast14. 1. Department of Radiotherapy, Amsterdam UMC, Amsterdam, the Netherlands. 2. Verbeeten Institute, Tilburg, the Netherlands. 3. Radiotherapeutisch Instituut Friesland, Leeuwarden, the Netherlands. 4. Department of Radiation Oncology, School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands. 5. Leids Universitair Medisch Centrum, Leiden, the Netherlands. 6. Department of Radiotherapy, Erasmus MC, Rotterdam, the Netherlands. 7. Department of Radiotherapy, Catharina Ziekenhuis, Eindhoven, the Netherlands. 8. Radiotherapiegroep, Deventer, the Netherlands. 9. Department of Radiotherapy, Zeeuws Radiotherapeutisch Instituut, Vlissingen, the Netherlands. 10. Department of Surgery, Amsterdam UMC, Amsterdam, the Netherlands. 11. Department of Biostatistic, Netherlands Cancer Institute, Amsterdam, the Netherlands. 12. Department of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, the Netherlands. 13. Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. 14. Department of Medical Oncology, Erasmus MC, Rotterdam, the Netherlands.
Abstract
PURPOSE: To analyze the effect of radiation dose escalation to the primary tumor on local tumor control in definitive chemoradiation (dCRT) for patients with esophageal cancer. PATIENTS AND METHODS: Patients with medically inoperable and/or irresectable esophageal carcinoma, referred for dCRT, were randomly assigned between a standard dose (SD) of 50.4 Gy/1.8 Gy for 5.5 weeks to the tumor and regional lymph nodes and a high dose (HD) up to a total dose of 61.6 Gy to the primary tumor. Chemotherapy consisted of courses of concurrent carboplatin (area under the curve 2) and paclitaxel (50 mg/m2) in both arms once a week for 6 weeks. The primary end point was local progression-free survival. RESULTS: Between September 2012 and June 2018, 260 patients were included. Squamous cell carcinoma (SCC) was present in 61% of patients, and 39% had adenocarcinoma (AC). Radiation treatment was completed by 94%, and 85% had at least five courses of chemotherapy. The median follow-up time for all patients was 50 months. The 3-year local progression-free survival (LPFS) was 70% in the SD arm versus 73% in the HD arm (not significant). The LPFS for SCC and AC was 75% versus 79% and 61% versus 61% for SD and HD, respectively (not significant). The 3-year locoregional progression-free survival was 52% and 59% for the SD and HD arms, respectively (P = .08). Overall, grade 4 and 5 common toxicity criteria were 12% and 5% in the SD arm versus 14% and 10% in the HD arm, respectively (P = .15). CONCLUSION: In dCRT for esophageal cancer, radiation dose escalation up to 61.6 Gy to the primary tumor did not result in a significant increase in local control over 50.4 Gy. The absence of a dose effect was observed in both AC and SCC.
PURPOSE: To analyze the effect of radiation dose escalation to the primary tumor on local tumor control in definitive chemoradiation (dCRT) for patients with esophageal cancer. PATIENTS AND METHODS: Patients with medically inoperable and/or irresectable esophageal carcinoma, referred for dCRT, were randomly assigned between a standard dose (SD) of 50.4 Gy/1.8 Gy for 5.5 weeks to the tumor and regional lymph nodes and a high dose (HD) up to a total dose of 61.6 Gy to the primary tumor. Chemotherapy consisted of courses of concurrent carboplatin (area under the curve 2) and paclitaxel (50 mg/m2) in both arms once a week for 6 weeks. The primary end point was local progression-free survival. RESULTS: Between September 2012 and June 2018, 260 patients were included. Squamous cell carcinoma (SCC) was present in 61% of patients, and 39% had adenocarcinoma (AC). Radiation treatment was completed by 94%, and 85% had at least five courses of chemotherapy. The median follow-up time for all patients was 50 months. The 3-year local progression-free survival (LPFS) was 70% in the SD arm versus 73% in the HD arm (not significant). The LPFS for SCC and AC was 75% versus 79% and 61% versus 61% for SD and HD, respectively (not significant). The 3-year locoregional progression-free survival was 52% and 59% for the SD and HD arms, respectively (P = .08). Overall, grade 4 and 5 common toxicity criteria were 12% and 5% in the SD arm versus 14% and 10% in the HD arm, respectively (P = .15). CONCLUSION: In dCRT for esophageal cancer, radiation dose escalation up to 61.6 Gy to the primary tumor did not result in a significant increase in local control over 50.4 Gy. The absence of a dose effect was observed in both AC and SCC.
Authors: Armando De Virgilio; Andrea Costantino; Carlo Castoro; Giuseppe Spriano; Bianca Maria Festa; Giuseppe Mercante; Davide Franceschini; Ciro Franzese; Marta Scorsetti; Andrea Marrari; Raffaele Cavina; Salvatore Marano Journal: J Cancer Res Clin Oncol Date: 2022-03-02 Impact factor: 4.553
Authors: Jana M Kobeissi; Charles B Simone; Lara Hilal; Abraham J Wu; Haibo Lin; Christopher H Crane; Carla Hajj Journal: Cancers (Basel) Date: 2022-06-10 Impact factor: 6.575
Authors: Michael D Chuong; Christopher L Hallemeier; Heng Li; Xiaorong Ronald Zhu; Xiaodong Zhang; Erik J Tryggestad; Jen Yu; Ming Yang; J Isabelle Choi; Minglei Kang; Wei Liu; Antje Knopf; Arturs Meijers; Jason K Molitoris; Smith Apisarnthanarax; Huan Giap; Bradford S Hoppe; Percy Lee; Joe Y Chang; Charles B Simone; Steven H Lin Journal: Front Oncol Date: 2021-10-19 Impact factor: 6.244
Authors: Marieke Pape; Pauline A J Vissers; Judith de Vos-Geelen; Maarten C C M Hulshof; Suzanne S Gisbertz; Paul M Jeene; Hanneke W M van Laarhoven; Rob H A Verhoeven Journal: Cancer Sci Date: 2022-01-25 Impact factor: 6.716
Authors: Gregory Vlacich; Andrew Ballard; Shahed N Badiyan; Matthew Spraker; Lauren Henke; Hyun Kim; A Craig Lockhart; Haeseong Park; Rama Suresh; Yi Huang; Cliff G Robinson; Jeffrey D Bradley; Pamela P Samson Journal: Clin Transl Radiat Oncol Date: 2021-06-29